Shoulder pain drug trial halted early

NCT ID NCT05722522

Terminated Symptom relief Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether the drug secukinumab could reduce pain and improve function in adults with moderate to severe rotator cuff tendinopathy, a common shoulder condition. Participants received either the drug or a placebo for 24 weeks. The trial was terminated early, and results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ROTATOR CUFF TENDINOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease of the tendon rotator cuff syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ROTATOR CUFF TENDINOPATHY

Contacts and locations

Locations

Healthy Life Research

Miami, Florida, 33184, United States
IRIS Research and Development

Plantation, Florida, 33324, United States
Millennium Clinical Trials

Westlake Village, California, 91361, United States
Novartis Investigative Site

San Miguel Tucuman, Tucumán Province, 4000, Argentina
Novartis Investigative Site

Buenos Aires, C1114AAP, Argentina
Novartis Investigative Site

San Miguel de Tucumán, 4000, Argentina
Novartis Investigative Site

Sofia, 1336, Bulgaria
Novartis Investigative Site

Québec, Quebec, G1V 3M7, Canada
Novartis Investigative Site

Brno, Czech Republic, 66250, Czechia
Novartis Investigative Site

Kolín, 280 02, Czechia
Novartis Investigative Site

Kota Kinabalu, Sabah, 88300, Malaysia
Novartis Investigative Site

Ponte de Lima, 4990-041, Portugal
Precision Clinical Research LLC

Sunrise, Florida, 33351, United States
West Clinical Research

Morehead City, North Carolina, 28557, United States
West Tennessee Research Institute

Jackson, Tennessee, 38305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.